How much should we pay for innovation? Fair pricing for pharmaceuticals Beth Woods, Centre for Health Economics
Event details
CHE Policy Forums
In 2021-22, prescription medicines cost the NHS in England £17.2 billion. Current policies, like NICE technology appraisal and the Voluntary Scheme, aim to incentivise innovation while ensuring access and affordability. This session explores recent research suggesting that prioritising long-term population health as the central objective of pharmaceutical pricing policy can help policymakers determine fair prices and appropriately distribute value between patients and pharmaceutical companies.
Beth Woods in discussion with Keith Derbyshire, former Chief Economist and Chief Analyst at the Department for Health and Social Care, and Adrian Towse of Office for Health Economics.
Please note: Those joining the event in person will be sent information on the location of the Forum in the days leading up to the event and those joining virtually will be emailed joining instructions prior to the event.